Abstract: The present invention relates to cosmetic or pharmaceutical topical compositions containing at least one cyclic nucleotide having its 2′ hydroxyl group replaced by a hydrogen atom for inhibiting phosphodiesterase activity. The phosphodiesterase inhibitor is in combination with a magnesium buffer and a cosmetically or pharmaceutically acceptable carrier. The invention also includes methods for treating or preventing inflammation or irritation such as is common in the skin disease, atopic dermatitis, which is known to be related to the uncontrolled activity of phosphodiesterase.

Abstract: A self-closing cap comprising a base having one or more holes and a lid movably mounted about the base. The lid has one or more holes, and is capable of occupying a first open position and a second closed position. In the first open position, the holes of the base align with the holes of the lid. In the second closed position, the holes of the base do not align with the holes of the lid. A spring means is provided between the base and the lid in order to automatically place the lid in the closed position. Further, the underside of the lid is provided with one or more protrusions which seal the holes of the base when the lid is in the closed position.